Arcturus Therapeutics Holdings Q3 2026 Results: Net Loss of $7.41M, Loss Narrows
Arcturus Therapeutics reported a decrease in total assets from $271.1 million at the end of 2025 to $215.3 million as of September 30, 2026, primarily driven by a reduction in cash and cash equivalents. The company's forward-looking statements highlight the termination of the CSL Collaboration Agreement and plans to advance its therapeutics pipeline, including ARCT-810 and ARCT-032, independently or with other partners.
- Key figure
- Net loss $7.41M